Cancer Research Cell Death Mechanisms and Cancer Therapy  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Debes, J. D.
Right arrow Articles by Tindall, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Debes, J. D.
Right arrow Articles by Tindall, D. J.
[Cancer Research 63, 7638-7640, November 15, 2003]
© 2003 American Association for Cancer Research


Advances in Brief

p300 in Prostate Cancer Proliferation and Progression

Jose D. Debes1, Thomas J. Sebo2, Christine M. Lohse3, Linda M. Murphy2, De Anna L. Haugen2 and Donald J. Tindall1

1 Departments of Urology
2 Laboratory Medicine/Pathology,
3 3Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota

Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300 is involved in androgen receptor transactivation. In the present work, we studied 95 patients with biopsy-proven PCa who underwent prostatectomy as treatment of their tumors between 1995 and 1998. We found that p300 correlated with in vivo proliferation (P = 0.009) as determined by MIB-I expression. Moreover, high levels of p300 in biopsies predicted larger tumor volumes (P < 0.001), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy, as well as PCa progression after surgery (P = 0.01).

Furthermore, we found that the disruption of p300 transcripts through small interfering RNA inhibited PCa cell proliferation both at the basal level and on interleukin 6 stimulation.

We conclude that p300 plays an important role in PCa cell proliferation, as well as PCa progression.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Shin, T.-D. Kim, F. Jin, J. M. van Deursen, S. M. Dehm, D. J. Tindall, J. P. Grande, J.-M. Munz, G. Vasmatzis, and R. Janknecht
Induction of Prostatic Intraepithelial Neoplasia and Modulation of Androgen Receptor by ETS Variant 1/ETS-Related Protein 81
Cancer Res., October 15, 2009; 69(20): 8102 - 8110.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. S.Q. Kortenhorst, S. Isharwal, P. J. van Diest, W. H. Chowdhury, C. Marlow, M. A. Carducci, R. Rodriguez, and R. W. Veltri
Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo
Mol. Cancer Ther., April 1, 2009; 8(4): 802 - 808.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. A Boorjian, H. V Heemers, I. Frank, S. A Farmer, L. J Schmidt, T. J Sebo, and D. J Tindall
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder
Endocr. Relat. Cancer, March 1, 2009; 16(1): 123 - 137.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. V. Heemers, T. J. Sebo, J. D. Debes, K. M. Regan, K. A. Raclaw, L. M. Murphy, A. Hobisch, Z. Culig, and D. J. Tindall
Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells
Cancer Res., April 1, 2007; 67(7): 3422 - 3430.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Okumura, M. Mendoza, R. M. Bachoo, R. A. DePinho, W. K. Cavenee, and F. B. Furnari
PCAF Modulates PTEN Activity
J. Biol. Chem., September 8, 2006; 281(36): 26562 - 26568.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
I. R. Logan, L. Gaughan, S. R. C. McCracken, V. Sapountzi, H. Y. Leung, and C. N. Robson
Human PIRH2 Enhances Androgen Receptor Signaling through Inhibition of Histone Deacetylase 1 and Is Overexpressed in Prostate Cancer.
Mol. Cell. Biol., September 1, 2006; 26(17): 6502 - 6510.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Dai, O. Kim, Y. Xie, Z. Guo, K. Xu, B. Wang, X. Kong, J. Melamed, H. Chen, C. J. Bieberich, et al.
Tyrosine Kinase Etk/BMX Is Up-regulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse
Cancer Res., August 15, 2006; 66(16): 8058 - 8064.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Stimson, M. G. Rowlands, Y. M. Newbatt, N. F. Smith, F. I. Raynaud, P. Rogers, V. Bavetsias, S. Gorsuch, M. Jarman, A. Bannister, et al.
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity
Mol. Cancer Ther., October 1, 2005; 4(10): 1521 - 1532.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. U. Agoulnik, A. Vaid, W. E. Bingman III, H. Erdeme, A. Frolov, C. L. Smith, G. Ayala, M. M. Ittmann, and N. L. Weigel
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Cancer Res., September 1, 2005; 65(17): 7959 - 7967.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. D. Debes, B. Comuzzi, L. J. Schmidt, S. M. Dehm, Z. Culig, and D. J. Tindall
p300 Regulates Androgen Receptor-Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6
Cancer Res., July 1, 2005; 65(13): 5965 - 5973.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Sato, M. Johnson, L. Zhang, S. S. Gambhir, M. Carey, and L. Wu
Functionality of Androgen Receptor-Based Gene Expression Imaging in Hormone Refractory Prostate Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3743 - 3749.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D.E. Clark, T.M. Errington, J.A. Smith, H.F. Frierson Jr., M.J. Weber, and D.A. Lannigan
The Serine/Threonine Protein Kinase, p90 Ribosomal S6 Kinase, Is an Important Regulator of Prostate Cancer Cell Proliferation
Cancer Res., April 15, 2005; 65(8): 3108 - 3116.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. D. Debes, T. J. Sebo, H. V. Heemers, B. R. Kipp, D. A. L. Haugen, C. M. Lohse, and D. J. Tindall
p300 Modulates Nuclear Morphology in Prostate Cancer
Cancer Res., February 1, 2005; 65(3): 708 - 712.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
B Kwabi-Addo, M Ozen, and M Ittmann
The role of fibroblast growth factors and their receptors in prostate cancer
Endocr. Relat. Cancer, December 1, 2004; 11(4): 709 - 724.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.